New research reveals a powerful link between blood biomarkers and the earliest signs of cognitive decline, offering a path toward more accessible and equitable diagnosis for a disease that affects millions.
For decades, diagnosing Alzheimer’s disease has been a complex, frustrating puzzle. By the time clear symptoms of memory loss and confusion appear, the underlying disease has often been progressing silently for years, causing irreversible damage to the brain. Current diagnostic tools, such as PET scans or spinal taps, are highly effective but also invasive, expensive, and not widely available. This creates a significant barrier to early diagnosis, which is critical for future treatments and for giving families time to plan. But what if we could catch the warning signs much earlier, with something as routine as a simple blood test?
That long-sought goal may be closer than ever, thanks to a landmark study from researchers at the University of California San Diego School of Medicine. In a paper published in JAMA Network Open, a team has identified a powerful connection between self-perceived cognitive changes and specific proteins in the blood. Their work not only highlights the promise of a more accessible diagnostic tool but also addresses a critical gap in dementia research by focusing on a community disproportionately affected by the disease.
A Study with a Critical Focus
The research centered on the Hispanic and Latino communities, which are projected to see the largest increase in Alzheimer’s prevalence in the coming decades and are thought to be about one and a half times more likely to develop the disease than non-Hispanic white adults. Despite this heightened risk, they have been significantly underrepresented in dementia research.
To address this, the UC San Diego team utilized data from the Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA), a sub-study of the largest long-term investigation of Hispanic and Latino health in the United States. They analyzed blood samples from 5,712 adults, aged 50 to 86, creating one of the most diverse and comprehensive datasets of its kind.
"Hispanic and Latino adults are thought to be more likely to get Alzheimer’s and related dementias," said senior author Dr. Hector M. González, a professor at UC San Diego School of Medicine. "Despite this, they’re still significantly underrepresented in Alzheimer’s and dementia research, which is something our study aimed to address."
Decoding the Clues in Our Blood
The researchers were looking for two things. First, they assessed participants for "subjective cognitive decline" (SCD)—the personal, self-reported feeling that one’s memory or thinking skills are slipping. This is often the very first sign that something is amiss, long before it can be picked up on standard cognitive tests.
Second, they measured the levels of several key proteins, or biomarkers, in the blood. These proteins can act as tell-tale signs of what’s happening inside the brain:
- Neurofilament light chain (NfL): A protein that leaks out of damaged nerve cells. High levels suggest active neurodegeneration.
- Glial fibrillary acidic protein (GFAP): A marker of inflammation in the brain, released by support cells called astrocytes when they respond to injury or disease.
- Phosphorylated tau 181 (ptau-181): A specific form of the tau protein, which forms the toxic "tangles" inside neurons that are a hallmark of Alzheimer’s disease.
- Amyloid-beta (Aβ42/40 ratio): The ratio of two proteins that form the infamous amyloid plaques that build up between brain cells in Alzheimer’s patients.
What the team discovered was both exciting and, in some ways, unexpected. They found clear and strong associations between what people were feeling and what their blood was showing.
Striking and Unexpected Findings
The results painted a detailed picture of the earliest stages of neurodegeneration. Higher blood levels of NfL (nerve damage) and GFAP (inflammation) were directly associated with individuals reporting a decline in their thinking, planning, and overall cognitive performance. Furthermore, higher levels of NfL and ptau-181 (tau tangles) were linked specifically to self-reported memory problems.
Perhaps the most surprising finding was what they didn’t see. The blood levels of amyloid-beta, the protein most famously associated with Alzheimer’s, showed no correlation with subjective cognitive decline in this study. This could suggest that in the very earliest stages, the damage and inflammation within the brain (reflected by NfL and GFAP) are more closely tied to a person’s perceived symptoms than the buildup of amyloid plaques.
Most promising of all, the link between the NfL biomarker and self-reported cognitive decline remained even in individuals who were otherwise considered cognitively healthy. This suggests that NfL could be a powerful, ultra-early indicator of trouble, flagging the very beginning of the disease process before it becomes clinically apparent.
"We need ways to identify underlying neurodegenerative diseases earlier in patients with cognitive symptoms," said corresponding author Dr. Freddie Márquez. "This study highlights the promise of blood-based biomarkers as a more accessible and scalable tool for understanding cognitive decline."
A Dose of Reality and the Road Ahead
While the findings are incredibly promising, the researchers are quick to add a note of caution. This blood test is not yet ready for widespread clinical use, and more research is needed to validate the results. Even when it does become available, it will be one tool in a larger diagnostic toolkit, not a standalone answer.
"It’s important to note that there’s still a lot we don’t know about the utility of blood-based biomarkers for Alzheimer’s detection," Márquez explained. "These tests have tremendous potential, but they should complement existing approaches, not replace them."
A positive result on a future blood test would likely be a signal for a clinician to proceed with more comprehensive evaluations. However, its power lies in its accessibility. A simple, affordable blood test could be administered in a primary care setting, bringing early screening to millions who lack access to specialized neurological centers. By focusing on a diverse, real-world population, this study ensures that the findings are relevant and can help bridge the gap in health equity.
The journey toward conquering Alzheimer’s is a long one, but this research provides a vital new map. The future of early detection may not require a complex brain scan, but instead, could begin with a single, hopeful drop of blood.
Reference
Márquez, F., Gonzalez, K., Valencia, D. F., Anita, N. Z., Tarraf, W., Stickel, A. M., Gallo, L. C., Sotres-Alvarez, D., Zhou, H., Levin, B. E., Goodman, Z. T., Yassa, M. A., Daviglus, M., Pirzada, A., Thyagarajan, B., & González, H. M. (2025). Association of plasma biomarkers with subjective cognitive decline in a diverse cohort of Hispanic and Latino adults. JAMA Network Open.
